Dong-A Socio Holdings Co., Ltd. (KRX: 000640)

Market Cap	723.21B
Revenue (ttm)	1.22T
Net Income (ttm)	51.02B
Shares Out	6.25M
EPS (ttm)	8,162.81
PE Ratio	14.17
Forward PE	9.93
Dividend	1,900.00 (1.63%)
Ex-Dividend Date	Jun 27, 2024

Volume	9,635
Open	113,100
Previous Close	113,700
Day's Range	113,000 - 117,600
52-Week Range	88,800 - 128,500
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It develops DA-1241 for the treatment of type 2 diabetes and non-alcoholic steatohepatitis; DA-1726, an oxyntomodulin analogue to treat obesity; DA-1229, a dipeptidyl peptidase-4 inhibitor class treatment for type 2 diabetes; DA-8010, a muscarinic M3 receptor antagonist for the treatment of overactive bladder; DMB-3115, a biosimilar of Stelara and an inflammatory disease treatment; DA-3880 to treat anemia; STP0404, an HIV-1 treatment drug;...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,530
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2023, Dong-A Socio Holdings's revenue was 1.13 trillion, an increase of 11.54% compared to the previous year's 1.01 trillion. Earnings were 57.99 billion, an increase of 419.96%.